GDF15 Biomarker: Blood Test, Normal Ranges & Longevity | YEARS

In modern preventive medicine, the focus is shifting from merely detecting disease to actively measuring health. One biomarker gaining significant attention in this new paradigm is Growth Differentiation Factor 15, or GDF15. While cholesterol is a household name, GDF15 remains a specialist marker, even though studies show that few other single biomarkers are so closely linked to the biological aging process and overall physiological stress.

It's unlikely your doctor measured this value at your last check-up. This is a feature of a system designed to treat illness, not to quantify wellness.

This article explains what GDF15 is, what levels are considered normal, and why this marker can be a cornerstone of a data-driven longevity strategy.

What Exactly Is GDF15? A Molecular Alarm Signal

GDF15 is a protein belonging to the transforming growth factor-beta (TGF-β) family. Think of it as a cellular smoke detector: when cells are under stress, they produce and secrete GDF15 into the bloodstream. This stress can have many causes:

• Mitochondrial dysfunction (inefficient cellular energy production)
• Oxidative stress
• Inflammatory responses
• DNA damage
• Hypoxia (oxygen deficiency)

GDF15 is not a specific marker for any single disease but rather a highly sensitive indicator of the body's overall physiological burden (IMD Labor Berlin, 2023). This is why it is sometimes referred to as a "stress hormone" or "longevity biomarker." It is measured with a simple blood test, typically using an ELISA (Enzyme-linked Immunosorbent Assay) method from a small serum sample.

GDF15 Normal Ranges: Reference Values by Age and Sex

GDF15 levels are highly dependent on age. A value that is elevated for a 30-year-old may be within the normal range for an 80-year-old. Therefore, an age- and sex-specific interpretation is essential.

In 2019, Welsh et al. published the most robust reference ranges for a healthy population in Circulation. The median values and upper limits (97.5th percentile) show a clear increase with age:

Two special cases deserve particular attention. Patients with known cardiovascular diseases often have a median GDF15 level of around 1,306 pg/mL (Welsh et al., 2019). During pregnancy, the placenta produces GDF15 in large quantities: levels can rise to a median of up to 19,311 pg/mL and fall again after birth (Fejzo et al., Nature 2023).

A single GDF15 value without context has little meaning. It must always be interpreted in relation to age, sex, clinical history, and other biomarkers.

What Do High GDF15 Levels Mean? Clinical Significance

An elevated GDF15 level is a non-specific but very sensitive signal that something in the body is out of balance. The list of conditions associated with elevated GDF15 levels is long and continues to grow.

Cardiovascular Diseases

In cardiology, GDF15 has significant prognostic value.

In acute coronary syndrome, the GDF15 level on admission predicted 3-year mortality better than the established GRACE 2.0 score (AUC 0.82 vs. 0.76) (Wollert et al., JAMA Cardiology 2017). For certain forms of heart failure, specifically HFpEF and HFmrEF, GDF15 is even more informative than the standard marker NT-proBNP (Fernandez-Cadenas et al., 2021). A Japanese study calculated a hazard ratio of 1.84 for GDF15 for hospitalizations due to heart failure (Teramoto et al., Heart and Vessels 2024). Patients with atrial fibrillation and elevated GDF15 levels have a higher risk of all-cause mortality and major adverse cardiovascular events (MACE) (Hijazi et al., JACC 2013).

Metabolic and Liver Diseases

Adolescents with non-alcoholic fatty liver disease (NAFLD) show significantly higher GDF15 levels, independent of their BMI. In studies, a reduction in liver fat also lowered GDF15 (Galuppo et al., JHEP Reports 2022). GDF15 is involved in inflammatory and scarring processes in the liver and interacts with other fibrosis markers like the FIB-4 index (Dietzel et al., European Journal of Clinical Investigation 2024).

Infections and Post-COVID Syndrome

Chronic fatigue after COVID-19 is one of the most consequential long-term problems of the pandemic. Researchers at Tohoku University found that a GDF15 level above 965 pg/mL during the acute infection is a strong predictor for developing Long COVID syndrome, with a sensitivity of 71.4% and a specificity of 83.3% (Ono et al., Respiratory Investigation 2024). GDF15 levels are also often elevated in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), suggesting underlying mitochondrial dysfunction (Melvin et al., PNAS 2019).

Cancer Early Detection

Many tumors produce GDF15. As a standalone screening tool, the marker is too non-specific, but it is promising in combination with other methods. In the detection of non-small cell lung cancer (NSCLC), GDF15 achieved high diagnostic accuracy in studies (AUC 0.93) (Wang et al., Clinica Chimica Acta 2017). The marker also shows good discriminatory power between patients with colorectal cancer and healthy controls (AUC 0.816) (Kim et al., Cancers 2021).

Biological Aging

GDF15 strongly correlates with epigenetic clocks that measure biological age, including DNAm GrimAge and PhenoAge. Individuals with genetically determined lower GDF15 levels in old age exhibit better physical function and a longer life expectancy (Justice et al., Aging Cell 2018). GDF15 is therefore not just a disease marker but also a reflection of the rate of aging.

A Deeper Dive: GDF15 and Mitochondrial Disease

One of the most important sources of GDF15 is stressed mitochondria. In primary mitochondrial myopathies (PMM), up to 86% of patients show elevated GDF15 levels. A threshold of 815 pg/mL can distinguish mitochondrial diseases from other muscle disorders with a sensitivity of 76% and a specificity of 88%. The high negative predictive value of 97% is particularly useful: a normal GDF15 level makes a relevant mitochondrial disease highly unlikely (Yatsuga et al., Annals of Neurology 2015).

Lifestyle and Therapeutic Approaches: Can You Lower GDF15?

An elevated level is not a final verdict but a starting point. Since GDF15 responds to cellular stress, it can be influenced by lifestyle changes.

Pharmacological Approaches (Research Stage)

The pharmaceutical industry is actively researching drugs that influence the GDF15 signaling pathway, primarily for treating cachexia or regulating appetite in obesity. Agents like YH34160 or QL1005 are in clinical trials and are still years away from market approval (Choi et al., Diabetes, Obesity and Metabolism 2024).

Exercise as a GDF15 Modulator

Exercise has an interesting effect here. A single intense workout can temporarily increase GDF15 levels by over 30%. This is not a bad sign. The body responds to this short-term stress with adaptations that lead to better long-term mitochondrial function and lower resting GDF15 levels (Klein et al., Journal of Clinical Endocrinology & Metabolism 2022). Regular exercise is one of the most effective methods for reducing basal cellular stress. Engaging in moderate endurance training three to four times a week creates a more favorable physiological baseline than any supplementation strategy.

Diet and Metabolic Stress

A diet that improves insulin resistance (measurable by the HOMA-IR index), reduces inflammation, and is rich in mitochondrial nutrients can also potentially lower GDF15 (IMD Labor Berlin, 2023). Mediterranean dietary patterns, which consistently improve inflammatory markers in intervention studies, offer a practical starting point.

Sleep and Stress Management

Chronic sleep deprivation and persistent high psychological stress increase the systemic stress load. Reducing sleep from eight to six hours measurably alters inflammatory parameters. A consistent sleep routine, combined with active recovery periods during the day, is therefore an underestimated lever for lowering GDF15 levels.

How GDF15 Compares to Other Key Biomarkers

ApoB measures the number of atherogenic particles, providing excellent information on cardiovascular risk. GDF15 measures the resulting cellular stress and inflammation. Together, they sharpen the cardiac risk profile much more than either marker alone.

NT-proBNP is a specific marker for the mechanical stretching of the heart muscle (hemodynamic stress). GDF15 captures systemic, inflammatory, and metabolic stress more broadly. In studies, patients with elevated levels of both markers carry by far the highest risk.

hs-CRP is the classic inflammation marker. GDF15 has proven to be a superior predictor of all-cause mortality because it predicts not only cardiovascular but also non-cardiovascular causes of death (Daniels et al., Journal of the American College of Cardiology 2008).

GDF15 at YEARS: From Data Point to Health Strategy

In the YEARS Core® program, GDF15 is a standard component of the lab panel, which includes over 87 biomarkers. The difference from standard diagnostics lies in the interpretation: your GDF15 value is not compared in isolation to the lab's reference range but is placed in the context of your entire diagnostic profile during a physician-led strategy session. How does your GDF15 relate to your HOMA-IR index, your ApoB, your hs-CRP, and the results of functional diagnostics like your VO₂max measurement? This synthesis creates a robust picture of your individual health status.

In the YEARS Evolve® and Ultimate® programs, this approach is deepened. GDF15 is combined with results from a whole-body MRI, a liquid biopsy (truCheck), or seven epigenetic clocks to determine biological age. An elevated GDF15 combined with accelerated epigenetic aging is a clear signal for targeted action.

The YEARS Ultimate® program includes monthly 1:1 coaching where therapeutic strategies are developed based on your data. Tracking your GDF15 level over months shows whether interventions in training, nutrition, and stress management are actually working at the cellular level.

Frequently Asked Questions About GDF15

Can I lower my GDF15 levels myself?

Not directly, but indirectly, yes. By consistently managing metabolic stress through diet and weight, regular exercise, optimized sleep, and stress reduction, you can reduce the root causes of cellular stress and thus potentially lower your GDF15 level.

Is a single GDF15 test result meaningful?

A single value provides an important snapshot, especially if it is significantly elevated. In longevity medicine, the trend over time is more informative. A decreasing GDF15 level after lifestyle changes demonstrates their effectiveness at a cellular level.

What's the difference between GDF15 and a biological clock?

Epigenetic clocks measure chemical changes to your DNA to estimate your biological age. GDF15 measures the current stress level of your cells. A persistently high GDF15 level can be one of the reasons why your biological clock is ticking faster.

What is a "good" GDF15 level for my age?

An ideal value lies in the lower range of the age-appropriate reference table, preferably below the median. Values approaching the upper 97.5th percentile should prompt a more detailed investigation, even in the absence of symptoms.

GDF15 as a Compass for Your Longevity

GDF15 is far more than just another lab parameter. It is a versatile and highly sensitive indicator of the burden your cells carry every day. In acute illnesses like a heart attack, it provides crucial prognostic information. However, its greatest potential lies in prevention.

An early-detected, slightly elevated GDF15 level can be the first quiet signal of subclinical mitochondrial dysfunction, chronic inflammation, or incipient insulin resistance—years before symptoms appear.

Measuring and correctly interpreting this value shifts the perspective from reactive, repair-based medicine to a proactive health strategy. It gives you and your physician data-driven insight into your cellular health and a concrete starting point for targeted interventions.

Have your GDF15 level interpreted by experts as part of a comprehensive panel of over 87 biomarkers. Schedule a consultation to learn more about your diagnostic day at YEARS.

---

Sources

• Choi, Y., et al. (2024). Efficacy and safety of YH34160, a novel long-acting GDF15 analogue, in combination with semaglutide in diet-induced obese mice. Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.15456.
• Daniels, L. B., et al. (2008). Relation of growth differentiation factor-15 to all-cause and cardiovascular mortality in ostensibly healthy older adults (from the Rancho Bernardo Study). The American Journal of Cardiology, 102(8), 1018-1024.
• Dietzel, A., et al. (2024). Interactions of growth differentiation factor 15 with clinical and lifestyle factors on MRI-derived measures of liver health: A cross-sectional population-based study. European Journal of Clinical Investigation, 54(1), e14136.
• Fejzo, M. S., et al. (2023). GDF15 linked to maternal risk of nausea and vomiting in pregnancy. Nature, 624(7992), 613-619.
• Fernandez-Cadenas, I., et al. (2021). Growth differentiation factor 15 and prognosis in heart failure with preserved or mid-range ejection fraction. ESC Heart Failure, 8(2), 1547-1556.
• Galuppo, M., et al. (2022). Growth differentiation factor 15 is a novel biomarker for non-alcoholic fatty liver disease in adolescents with obesity. JHEP Reports, 4(1), 100407.
• Hijazi, Z., et al. (2013). GDF-15 and risk of major bleeding and cardiovascular events in patients with atrial fibrillation: the ARISTOTLE trial. Journal of the American College of Cardiology, 62(16), 1474-1483.
• IMD Labor Berlin. (2023). GDF-15: Ein Biomarker für mitochondrialen Stress. IMD-Berlin.de.
• Justice, J. N., et al. (2018). Senescent cells in aging and age-related disease: a review. Aging Cell, 17(1), e12668.
• Kim, B. C., et al. (2021). Diagnostic and Prognostic Roles of GDF15 in Patients with Colorectal Cancer. Cancers, 13(3), 578.
• Klein, C., et al. (2022). Circulating GDF15 is a novel biomarker of physical activity. The Journal of Clinical Endocrinology & Metabolism, 107(1), e329-e339.
• Melvin, A., et al. (2019). A mitochondrial crisis in myalgic encephalomyelitis/chronic fatigue syndrome: results of a bioenergetic-focused round-table. Proceedings of the National Academy of Sciences, 116(44), 22359-22360.
• Ono, Y., et al. (2024). Growth differentiation factor-15 as a biomarker of post-COVID-19 condition: a prospective cohort study. Respiratory Investigation, 62(2), 241-248.
• Teramoto, T., et al. (2024). Association between serum GDF-15 and risk of heart failure hospitalisation in the general population: a prospective cohort study. Heart and Vessels, 39, 444-453.
• Wang, M., et al. (2017). Diagnostic and prognostic value of GDF15 in patients with non-small cell lung cancer. Clinica Chimica Acta, 473, 129-135.
• Welsh, P., et al. (2019). GDF15 and its utility in clinical medicine. Circulation, 140(18), 1479-1481.
• Wollert, K. C., et al. (2017). Growth Differentiation Factor 15 for Risk Stratification and Guidance of P2Y12 Inhibitor Therapy in Non-ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2(5), 526-534.
• Yatsuga, S., et al. (2015). Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Annals of Neurology, 78(5), 814-823.